Healthcare
Live Price
Offline$177.55
+0.00% today
1Y Change
-16.21%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 256 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tecan Group AG (TCHBF) is a Healthcare stock with a market cap of $1.52B and listed on OTC. The stock last traded around $177.55 and down 16.2% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -5.5%, EPS growth of -264.9%, a dividend yield of 2.5%. What stands out right now is revenue -5.5%, EPS -264.9%, free cash flow -12.9% with operating margin 5.1% and ROIC 3.1%. The dividend matters to the case here, with a current yield around 2.5%. Valuation is more restrained than many high-expectation growth names at price/sales 1.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TCHBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TCHBF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TCHBF Max Drawdown
-26.73%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TCHBF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$946.6M
-17.3% YoY
FY Net Income
$121.7M
+0.4% YoY
Free Cash Flow
$130.1M
+41.4% YoY
Revenue Growth
-5.5%
EPS Growth
-264.9%
Gross Margin
35.2%
Net Margin
-12.5%
Income statement
CHF
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 883M | 934M | 1.1B | 1.1B | 947M |
| Gross Profit | 311M | 321M | 390M | 438M | 409M |
| Operating Income | 42M | 76M | 136M | 148M | 146M |
| EBITDA | 42M | 148M | 206M | 211M | 201M |
| Net Income | -111M | 68M | 132M | 121M | 122M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CHF
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 176M | 154M | 133M | 111M | 121M |
| Total Assets | 1.7B | 2.1B | 2.1B | 2.1B | 2.0B |
| Total Liabilities | 547M | 686M | 725M | 758M | 771M |
| Shareholder Equity | 1.2B | 1.4B | 1.3B | 1.4B | 1.2B |
| Total Debt | 218M | 321M | 316M | 308M | 314M |
| Net Debt | 42M | 167M | 183M | 196M | 193M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
170M
+32.4% YoY
Capital Expenditures
40M
-9.6% YoY
Free Cash Flow
130M
+41.4% YoY
Key ratios
Gross Margin
35.2%
Operating Margin
5.1%
Net Margin
-12.5%
ROE
-9.1%
Debt / Equity
0.19x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.